

12/2/20njm

INTRAHEPATIC CHOLESTASIS OF PREGNANCY MANAGEMENT GUIDELINES

Alaska Native Medical Center

Background

Intrahepatic cholestasis of pregnancy (ICP) is a common disorder in our obstetric population, with an incidence of 4.9% on a recent chart survey. Symptoms usually develop in the third trimester, characterized by severe pruritus without a rash.

‘Severe’ pruritus is characterized by pruritus, which may be intolerable. It is often generalized but predominates on the palms and the soles of the feet and is worse at night. At minimum there should be a history of insomnia due to the constant scratching, including the soles and palms, observed scratching during clinical encounters, and excoriations found on exam.

The pathophysiology involves abnormal bile acid metabolism, with deposition of bile acids in the maternal tissues and the placenta. It is commonly (approximately 70% of cases) accompanied by elevated maternal serum total bile acids (over 10 $\mu\text{mol/L}$) with a predominance of the unconjugated, or cholic acid, fraction (Cholic acid $> 3 \mu\text{mol/L}$). Abnormal liver function tests (transaminase levels in the 60-200 range U/L, and alkaline phosphatase 200-400 U/L range) are typically present, although hyperbilirubinemia with clinical jaundice is uncommon.

Apart from the severe maternal symptomatology, the chief perinatal risk is intrauterine fetal demise (incidence 1-9%), which is typically very poorly predicted by antenatal fetal surveillance. Late preterm birth (34-36 weeks), fetal intolerance of labor, and meconium stained fluid are also more common in these pregnancies. Maternal symptoms resolve promptly after delivery, but there is a 40-70% recurrence rate in subsequent pregnancies. In a review of over 1 million women, it was found that intervention at a TBA of > 40 show benefit outweighing the risks. (Geenes 2014)

Many pregnant women will have itching without abnormal laboratory results. In our own data set this characterized 23% of women. In ICP, severe pruritus will often antedate elevation of serum bile acids by 2-4 weeks. Women with mild pruritus but normal bile acids $\times 2$ should be classified as “pruritus gravidarum”. These women will usually not be scratching during their clinical encounters, not be found to be excoriated, will not give a history of insomnia due to the constant itching, and have not required medical treatment.

In contrast, ‘Severe Pruritus of Pregnancy’ includes those patients with severe pruritus with TBA < 10 .

There are three subcategories:

- Severe Pruritus of Pregnancy: on Ursodiol
- Severe Pruritus of Pregnancy: not on Ursodiol
- Severe Pruritus of Pregnancy: other lab criteria (see non-bile acid metrics below)

The Severe Pruritus of Pregnancy category includes those patients with severe pruritus who have normal bile acids and liver functions but have been started on ursodiol empirically by another provider. These women no longer have severe symptoms and have TBA < 10. Generally, one should wait to have the diagnosis confirmed before starting ursodiol. (Ursodiol will lower serum bile acids and then make it impossible to establish the diagnosis.) In this case the final diagnosis will need to be a clinical decision of the individual provider dependent on assessment of severity of the symptoms.

Lastly, it is not entirely clear from the literature which total bile acid level to plan the patient's delivery on, e. g., the maximum TBA or the most recent TBA just before delivery (a.k.a. 'proximate' TBA). After reviewing dozens of articles, most of the papers do not explicitly state which level they use (Maximum TBA vs proximate TBA).

Of the papers which do mention which TBA they use - the maximum level is the most frequently mentioned. (12, 16, 24, 25, 26) Ironically when some the papers that use the maximum level as a cut-off do mention their patient's proximate TBA, the proximate level was almost identical to the maximum level. This suggests their patients did not actually take their ursodiol, which should have significantly decreased the TBA.

In any case, once a patient has started ursodiol her TBAs will decrease, so that factor alone would underscore the need to use the maximum TBA and would be a better marker than the current medicated TBA.

Considering the sparse data at this time, as a department we have decided to use the MAXIMUM total bile acid level to determine management, until a better marker is developed in the literature.

Management

a. Diagnosis

1. Patients in our population should be asked about severe itching in previous pregnancies and their records reviewed to see if the diagnosis of ICP was suspected.
2. Patients who present with symptoms of severe pruritus, but without an obvious rash, may or may not have ICP, and require a workup.
3. An attempt should be made to confirm the diagnosis by obtaining a random total bile acids level and liver function tests.
4. Patients in our population with a history of a prior stillbirth should also be considered for screening for ICP in the early third trimester.

b. Diagnostic Categories (See also Table 1)

Severe ICP-A	TBA > 100
Severe ICP-B	TBA \geq 40 < 100
Mild ICP	TBA \geq 10 < 40

Severe Pruritus -on Ursodiol	TBA < 10	
Severe Pruritus - other lab criteria	TBA < 10	(See non-bile acid metrics)
Severe Pruritus - not on Ursodiol	TBA < 10	
Pruritus Gravidarum*	TBA < 10	

Other considerations

-If two sets of bile acids and liver functions are normal, the patient's symptoms are severe, and they are not taking ursodiol - then they are diagnosed with 'Severe Pruritus of Pregnancy - not on Ursodiol'. (Table 1, Figure 1)

-*If two sets of bile acids and liver functions are normal and the patient's symptoms are not severe, they are diagnosed with 'Pruritus Gravidarum'. (Table 1, Figure 1)

-If the patient ≤ 32 wks with prior severe pruritus has already been started on ursodiol for 'Severe Pruritus of Pregnancy', but has normal labs q wk x2, then discontinue the ursodiol and continue weekly labs.

-If the pruritus remains severe and the TBA < 10, then follow this patient as 'Severe Pruritus of Pregnancy – not on Ursodiol'. (Table 1, Figure 1)

-If the pruritus becomes non-severe and the TBA < 10, then follow this patient as 'Pruritus Gravidarum'. (Table 1, Figure 1)

-If liver functions are elevated, but TBA < 10, then serologic studies for hepatitis should be obtained. (Women with hepatitis A are usually symptomatic with nausea, malaise, jaundice, etc.... but do not usually have pruritus.)

-Cholelithiasis is also more common in women with ICP, but the symptoms are usually quite different (abdominal and shoulder pain, vomiting, etc, but usually not pruritus).

b. Therapy

1. The current mainstay of symptomatic therapy is ursodiol, but it is unclear if it improves maternal symptoms or perinatal outcomes. Less than 10% of ursodiol is absorbed, its site of action being in the enterohepatic circulation, where it enhances bile acid excretion. It is an FDA pregnancy class B drug. The starting dose is 15 mg/kg/day, usually divided into 3 doses. If the patient has not experienced relief within a week, the dose may be increased to 25 mg/kg/day. Ursodiol is manufactured as 300 mg capsules and the dose may be rounded off as convenient.
2. Women who have severe symptoms and have normal bile acids, should wait to have the diagnosis confirmed before starting ursodiol. (Ursodiol will lower serum bile acids and then make it impossible to establish the diagnosis.) The final diagnosis will need to be a clinical decision of the individual provider dependent on assessment of severity of the symptoms.
3. Other agents to consider are rifampin or cholestyramine.
 - The total daily dose of rifampin ranges from 300 to 1200 mg, administered in divided doses. Pruritus improved in most patients and many had a reduction in bile acid and/or transaminase levels.
 - Cholestyramine is given orally in divided doses starting at 2 to 4 g per day and gradually increased to a maximum dose of 16 g per day, if needed for symptom control. However, its effect on pruritus in ICP is limited and cholestyramine may cause constipation, abdominal discomfort, and malabsorption of fat including fat-soluble vitamins (eg,

vitamin K), especially at high doses (eg, >4 grams per day).

4. Antihistamine therapy with diphenhydramine or hydroxyzine is typically *not* effective for symptom relief. However, administration of these drugs at bedtime, when symptoms are usually worse, may help the mother to sleep, as they usually produce drowsiness.

c. Laboratory monitoring

1. If a patient is taking ursodiol (ursodeoxycholic acid) and your lab reports ursodeoxycholic acid in the fractionated results, then please subtract the synthetic ursodeoxycholic acid to produce an amended TBA which does not reflect the medication the patient is taking.
2. In known ICP with TBAs < 100: total bile acids and LFTs should be monitored on a weekly basis after 36 wks.
3. In Severe pruritus of pregnancy: total bile acids and LFTs should be monitored on a weekly basis.
4. In Pruritus Gravidarum: total bile acids and LFTs should be monitored on a q 2 week basis until negative x2.

d. Non-bile acid metrics

From 2003-2013 the ANMC MFM and OB/GYN departments performed an extensive Quality Improvement evaluation as we learned about the high prevalence of ICP in our population. Among other things we learned that the total bile acid level often lagged behind the symptoms of severe pruritus by 2 to several weeks. The delay in the bile acid tests themselves is compounded by the time lag for obtaining the results.

We also learned that the following indicators became positive in association with severe symptoms before the total bile acids were elevated. As such, we use the following non-total bile acid metrics as an indication for delivery at 39 weeks and weekly NSTs- if the patient did not have hepatitis, steatosis, or cholelithiasis.

Cholic acid ≥ 3 umol/L

Total Bilirubin
 ≥ 1.0 mg/dL

AST 2x normal lab limits

ALT 2x normal lab limits

Alk. phosphatase
 ≥ 300 U/L

e. Fetal Surveillance

1. Women with a diagnosis of ICP should undergo fetal surveillance beginning at 32 weeks. The patient should also be instructed in recording daily fetal kick counts. (Table 1)

2. Patients who present with uncertain dates should have an initial dating ultrasound, followed by a repeat ultrasound in 3 weeks to confirm the due date (if feasible within the time frame of the pregnancy), and help establish the time for induction. If doubt still exists as to the actual EDD, amniocentesis for fetal lung maturity may be offered at the discretion of the provider, or after consultation with MFM as indicated.
3. Patients with pruritus gravidarum should receive bile acid and LFT testing q 2 wks until negative x2, but no antenatal testing nor early delivery for this indication alone.

Severe ICP-A	TBA > 100	BPP/wk and NST 2x /wk
Severe ICP-B	TBA \geq 40 < 100	BPP/wk and NST /wk
Mild ICP	TBA \geq 10 < 40	BPP/wk and NST /wk
Severe Pruritus -on Ursodiol	TBA < 10	NST /wk
Severe Pruritus - other lab criteria	TBA < 10	NST /wk
Severe Pruritus - not on Ursodiol	TBA < 10	No testing
Pruritus Gravidarum*	TBA < 10	No testing

f. Delivery

Due to the risk of intrauterine demise, it is recommended that women with the criteria below receive early delivery based on these management plans.

		Ripen / Delivery Range
Severe ICP-A	TBA \geq 100	36 - 36 6/7
Severe ICP-B	TBA \geq 40 < 100	37 - 37 6/7
Mild ICP	TBA \geq 10 < 40	38 - 38 6/7
Severe Pruritus -on Ursodiol	TBA < 10	39 - 39 6/7
Severe Pruritus - other lab criteria	TBA < 10	39 - 39 6/7
Severe Pruritus - not on Ursodiol	TBA < 10	39 - 39 6/7
Pruritus Gravidarum	TBA < 10	Other obstetric indications

Other

- Those ICP patients delivering at field facilities, if the maximum TBA \geq 10 < 40, then cervical ripening or delivery can begin at 39 0/7.
- If the maximum TBA is \geq 40 then the field patient should be referred to ANMC at 37 0/7
- Women with an unfavorable cervix are candidates for out-patient pre-induction cervical ripening with misoprostol if fetal surveillance is reassuring.
- Draw bile acids and LFTs on all categories of patients upon admission to L/D, except Pruritus Gravidarum
- Post-partum:
 - Patients with TBA \geq 10 during pregnancy should get repeat TBAs at 6 wk PP. If the postpartum TBA \geq 10, then refer to Hepatology
 - Hormonal contraception may be offered, as very few women will have recurrence of symptoms on such therapy.
- Patients in our population with a history of a prior stillbirth should be considered for screening for ICP in the early third trimester.

Table 1			
History, symptoms, signs	Lab abnormalities*	Prior Treatment	Current Treatment
Severe ICP-A			
<p>(Any one of these)</p> <p><u>History</u> Generalized ‘severe’ pruritus -intolerable -predominates on the palms and the soles of the feet -worse at night -history of insomnia due to the constant scratching</p> <p><u>Exam</u> -observed scratching during clinical encounters -excoriations found on exam</p>	Maximum TBA \geq 100		Ursodiol starting at 15 mg/kg divided BID BPP q wk NST 2x/wk Cervical ripening or cesarean delivery at 36 0/7 -36 6/7 wks
Severe ICP-B			
History and exam as above	Maximum TBA \geq 40 <100		Ursodiol starting at 15 mg/kg divided BID TBA and LFTs q wk p 36 wk BPP q wk NST q wk Cervical ripening or cesarean delivery at 37 0/7 -37 6/7 wks

Mild ICP			
History and exam as above	TBA $\geq 10 < 40$		<p>Ursodiol starting at 15 mg/kg divided BID</p> <p>TBA and LFTs q wk p 36 wk</p> <p>BPP q wk NST q wk</p> <p>Cervical ripening or cesarean delivery at 38 0/7 – 38 6/7 wks</p>
Severe Pruritus of Pregnancy – on ursodiol			
History and exam as above	TBA < 10	<p>If ≤ 32 wks with prior severe pruritus on ursodiol, but has normal labs q wk x2, then discontinue ursodiol and continue weekly labs.</p> <p>-if TBAs become abnormal, then deliver per TBA level</p> <p>-if sx become non-severe off ursodiol and repeat BA are normal, then treat as pruritus gravidarum</p>	<p>TBA and LFTs q wk</p> <p>NST q wk</p> <p>-perform cervical ripening or cesarean delivery at 39 0/7 - 39 6/7 weeks</p>
Severe Pruritus of Pregnancy – not on ursodiol			
History and exam as above	TBA < 10	<p>Off ursodiol</p> <p>-if TBAs become abnormal, then</p>	<p>TBA and LFTs q wk</p> <p>No antenatal testing</p>

		<p>deliver per TBA level</p> <p>-if sx become non-severe off ursodiol and repeat BA are normal, then treat as pruritus gravidarum</p>	<p>-perform cervical ripening or cesarean delivery at 39 0/7 - 39 6/7 weeks</p>
Severe Pruritus of Pregnancy – other lab criteria			
History and exam as above	<p>TBA < 10</p> <p>Any one of these: Cholic acid \geq 3 μmol/L</p> <p>Total Bilirubin \geq 1.0 mg/dL</p> <p>AST 2x normal lab limits</p> <p>ALT 2x normal lab limits</p> <p>Alk. phosphatase \geq 300 U/L</p> <p>-no evidence of steatosis, hepatitis, or cholelithiasis</p>		<p>Ursodiol starting at 15 mg/kg divided BID</p> <p>TBA and LFTs q wk</p> <p>NST q wk</p> <p>-perform cervical ripening or cesarean delivery at 39 0/7 - 39 6/7 weeks</p>
Pruritus gravidarum			
Pruritus, but non-severe	TBA < 10	Not on ursodiol	<p>TBA and LFTs q 2 wks until negative x2</p> <p>No antenatal testing</p> <p>Delivery for usual obstetric indications</p>

References


1. Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. *Lancet*. 2019;394(10201):849-860. doi:10.1016/S0140-6736(19)31270-X
2. Ovadia C et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analysis. *Lancet* 2019 Mar 2;393(10174):899-909.
3. Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. *Cochrane Database of Systematic Reviews* 2020, Issue 7. Art. No.: CD000493. DOI: 10.1002/14651858.CD000493.pub3. (Accessed 9/26/20)
4. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. *Obstet Gynecol*. 2014 Jul;124(1):120-33.
5. Henderson CE, Shah RR, Gottimukkala S, Ferreira KK, Hamaoui A, Mercado R. Primum non nocere: how active management became modus operandi for intrahepatic cholestasis of pregnancy. *Am J Obstet Gynecol*. 2014 Sep;211(3):189-96.
6. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Hepatology. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. 2014 Apr;59(4):1482-91
7. Royal College of Obstetricians and Gynaecologists. *Obstetric Cholestasis*, 2nd edition, Green-top Guideline No. 43 Published 5/19/2011 (Accessed 9/26/20)
8. Mays J, Lee-Hwang G, Fuks A, et al. Induction of labor at less than 38 weeks in cholestasis of pregnancy: a 6-year cohort. *Am J Obstet Gynecol* 2013; 208 (1): S84 (abstract 172).
9. Rook M, Vargas J, Caughey A, Bacchetti P, Rosenthal P, Bull L. Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort. *PLoS One*. 2012;7(3):e28343
10. Chappell LC, Gurung V, Seed PT, Chambers J, Williamson C, Thornton JG; PITCH Study Consortium. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. *BMJ*. 2012 Jun 13;344:e3799.
11. Kondrackiene J, Beuers U, Kupcinskis L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. *Gastroenterology*. 2005 Sep;129(3):894-901.
12. Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. *Hepatology*. 2005 Dec;42(6):1399-405.
13. Riely CA, Bacq Y. Intrahepatic cholestasis of pregnancy. *Clin Liver Dis* 2004; 8:1-13.
14. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. *Hepatology* 2004; 40:467-474.
15. Roncaglia N, Locatelli A, Arreghine A, et al. A randomized controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. *BJOG* 2004; 111: 17-21.

16. Williamson C, Hems LM, Goulis DG, et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. *BJOG* 2004; 111:676-81.
17. Savander M, Ropponen A, Avela K, et al. Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. *Gut* 2003; 52:1025-9.
18. Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. *Curr Treat Options Gastroenterol* 2003; 6:123-132.
19. Brites D. Intrahepatic cholestasis of pregnancy: Changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. *Ann Hepatol* 2002; 1:20-28.
20. Kenyon AP, Piercy CN, Girling J, Williamson C, Tribe RM, Shennan AH. Obstetric cholestasis, outcome with active management: a series of 70 cases. *BJOG*. 2002 Mar;109(3):282-8.
21. Zapata R, Sandoval L, Palma J, et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: A 10-year experience on its efficacy, safety and perinatal outcome (abstract). *Gastroenterology* 2000; 118:A1008.
22. Heinonen S, Kirkinen P. Pregnancy outcome with intrahepatic cholestasis. *Obstet Gynecol* 1999; 94:189-93.
23. Serrano MA, Brites D, Larena MG, et al. Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. *J Hepatol* 1998;28:829-34.
24. Brites D, Rodrigues CM, Oliveira N, Cardoso M, Graça LM. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. *J Hepatol*. 1998 Jan;28(1):91-8.
25. Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized double-blind study controlled with placebo.. *J Hepatol* 1997; 27:1022-8.
26. Meng LJ, Reyes H, Axelson M, et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. *Hepatology* 1997; 26:1573-8.
27. Alsulyman WM, Ouzounian JG, Ames-Castro M, Goodwin TM. Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. *Am J Obstet Gynecol* 1996; 175:957-60.
28. Rioseco AJ, Ivankovic MB, Manzur A, et al. Intrahepatic cholestasis of pregnancy: a retrospective case-control study of perinatal outcome. *Am J Obstet Gynecol* 1994; 170:890-5.

Revised 12/2/20 njm
Revised 4/21/19 njm
Revised 6/1/18 njm
Revised 3/23/18 njm
Reviewed 7/24/16 njm
Reviewed 11/17/14 njm

Reviewed 4/8/13 njm
Reviewed 1/15/13 njm
Reviewed 11/3/10 njm
Reviewed 3/5/09 njm
Written 5/1/08 gg

Pruritus



December 2, 2020